News & Media | Lee's Pharmaceutical
20 DEC 2018

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

PALO ALTO, CA, AND HONG KONG – December 19, 2018 – Auransa, Inc., an artificialintelligence (AI)-driven pharmaceutical company developing precision medicines in areas ofsignificant unmet medical need……





News & Media

20/10/2020
Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets
Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm" or "the Company"; Hong Kong stock code: 0950.HK), a research-based biopharmaceutical company, is pleased to announce that a wholly owned subsidiary of its associated company, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd (“ZKO”) has recently entered into an exclusive licensing agreement with Nevakar Inc. ("Nevakar"), a US-based privately held, late-stage, biopharmaceutical company developing multiple innovative medications in the ophthalmic and hospital injectable areasfor the development and commercialization of NVK-002 in Greater China (The People’s Republic of China (“PRC”), Hong Kong SAR, Macau SAR and Taiwan), South Korea and the Southeast Asian territories1. NVK-002 is a preservative-free, novel topical eye treatment for slowing the progression of myopia in children and is currently in a Phase 3 clinical trial study ("Childhood Atropine for Myopia Progression" or “CHAMP“ study) in the US and Europe.
Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm" or "the Company"; Hong Kong stock code: 0950.HK), a research-based biopharmaceutical company, is pleased to announce that a wholly owned subsidiary of its associated company, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd...

29/10/2010
Grand Opening of Headquarters of Powder Pharmaceuticals
[Hong Kong] Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharmaceutical” or the “Group”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, announced that its associated company Powder Pharmaceuticals, Incorporated (PPI) has opened a headquarters at the Hong Kong Science and Technology Park on 29 October 2010. This is PPI’s first manufacturing facility in Hong Kong, which will strengthen its foundation for the development of Zingo, a novel pharmaceutical product for pain management.

Located on the ground floor of the Wireless Centre at the Hong Kong Science and Technology Park in Shatin, the office covers an area of over 13,000 square feet with total 14 staffs. PPI is owned by Lee’s Pharmaceuticals, China Opportunity, a renowned fund in China and Sigma-tau. PPI acquire certain assets of and the global interest in Zingo and its powder intradermal injection system. Zingo, also named Lidocaine Hydrochloride Monohydrate, is a new kind of analgesic applied on intact skin to provide painkilling effect prior to venipuncture and intravenous cannulation. Zingo, which has received approval for sales from Food and Drug Administration (FDA) in the United States, is used for partial analgesia prior to veni-puncture and intravenous cannulation for both kids and adults. PPI will focus on manufacturing, developing and selling Zingo and related products.

Mr. Geoffrey F. Woodhead, Assistant Commissioner of Innovation and Technology Commission, Mr. E Anthony Tan, CEO of Hong Kong Science and Technology Park, Mr. Ugo Di Francesco, CEO of Sigma-tau, Mr. Niccolo Magnoni and Mr. Fabio De Rosa, Director of PPI, together with Board members of Lee’s Pharmaceutical, Mr. Lee Siu Fong, Chairman of Lee’s Pharmaceutical, Ms. Leelalertsuphakun Wanee, Dr. Benjamin Li and Mr. Mauro Bove, hosted the grand opening ceremony.

Dr. Benjamin Li, CEO of Lee’s Pharmaceutical said, “I am very pleased to witness the establishment of PPI’s first manufacturing base and would like to extend my gratitude to my partner for its continuous support and trust. The opening marks the success of the production and development business of Lee’s Pharmaceutical. The Board expects the business of PPI to grow in the medium to long run. This transaction represents a good investment opportunity for the Group and a more solid foundation for future growth.”
[Hong Kong] Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharmaceutical” or the “Group”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, announced that its associated company Powder Pharmaceuticals, Incorporated (PPI) has...

22/12/2008
Anhui Government Official Visited Zhaoke Pharmaceutical (Hefei) Co. Ltd.
2008年12月22日晚9点,安徽省委常委、合肥市委书记孙金龙率省市及高新区领导一行20余人,视察了兆科药业(合肥)有限公司,孙书记对于公司的建设和发展以及取得的成就给予了高度的评价。
在公司的会议室,孙书记等省市领导兴致勃勃地听取了公司董事长李小羿博士对公司目前经营状况、发展目标、竞争优势,以及在新产品研发等方面的介绍。
孙书记还详细询问了公司在研新药的情况及发展前景,同时非常关心公司在发展过程中碰到什么困难,需要政府哪方面的支持。李博士向孙书记汇报了公司在科技项目投入方面的工作和取得的进展,并与孙书记进行了深入的交流。孙书记对于生物制药这一高科技产业给予了高度评价,表示会加大对于公司科研项目的支持力度,希望兆科药业加快发展,争创国内国际一流企业。
视察结束后,孙书记与董事长李博士、常务副总陈跃生合影留念,勉励兆科药业把握发展机遇,开创更加美好的未来。
2008年12月22日晚9点,安徽省委常委、合肥市委书记孙金龙率省市及高新区领导一行20余人,视察了兆科药业(合肥)有限公司,孙书记对于公司的建设和发展以及取得的成就给予了高度的评价。
在公司的会议室,孙书记等省市领导兴致勃勃地听取了...

15/06/2005
Distribution Agreement to market Somatostatin
(Hong Kong, 15 June 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed an Agreement with GP-Pharm S.A., Spain for the distribution and marketing of Somonal®~Somatostatin 3mg ampoules, throughout Hong Kong and the People's Republic of China.

Somatostatin was first discovered in hypothalamic extracts and identified as a hormone that inhibited secretion of growth hormone. Subsequently, Somatostatin was found to be secreted by a broad range of tissues, including pancreas, intestinal tract and regions of the central nervous system outside the hypothalamus. Somonal® consists of Somatostatin freeze dried ampoules containing 3 mg of the active substance for dissolution purpose, is indicated for used clinically to treat carcinoid syndrome, enterocutaneous and pancreatic fistula, VIPomas, glucagonomas, severe esophageal varices bleeding.

Somatostatin is widely prescribed in China for acute variceal bleeding. Due to the high prevalence of HBV infection, China has a relatively high number of people suffered from cirrhosis and the subsequent acute esophageal varices bleeding caused by portal vein hypertension. The market for product like Somatostatin in China is quite attractive.

"We're extremely pleased to establish this distribution partnership with GP-Pharm S.A.,," stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "This is the seventh product so far we have licensed-in for distribution in China from our partners in Italy and Spain. This product will allow the Group to enter into a new therapeutic area." The Group believe that successful implementation of this strategy will further expand its market shares, enrich its product pipeline and to broaden its revenue base.

About GP-Pharm

GP-Pharm P.A. is a pharmaceutical company based in Spain within the Lipotec Group whose foundation dates back from 2001. The company is undertaking the pharmaceutical and the clinical development of new products containing hormones and Cytotoxic drugs.

About Lee's

Lee's Pharmaceutical Group, as a research-driven and market-oriented biopharmaceutical group, is actively pursuing for developing proprietary products and licensing technology/product from overseas prestigious biopharmaceutical institutions and companies.

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.

For further information, please contact:
Vivian Fung
Tel: (852)2314-1282
Fax: (852)2314-1708
Email: info@leespharm.com
(Hong Kong, 15 June 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed an Agreement with GP-Pharm S.A., Spain for the distribution and marketing of Somonal®~Somatostatin 3mg ampoules, throughout...

29/03/2005
Market Isosorbide Mononitrate in HK and China
(Hong Kong, 29 March 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed a Supply and Distribution Agreement with Marvecs Services S.r.l. for the distribution and marketing of Vasdilat® slow-released capsules (Isosorbide Mononitrate), throughout Hong Kong and the People's Republic of China.

Vasdilat®~Isosorbide Mononitrate (ISMN), is a type of vasodilator with effects on both arteries and veins. The pain of coronary heart disease (angina) usually occurs when the heart requires more blood and oxygen than its blood vessels supplying the heart can deliver. Our ISMN capsule contains 30mg of isosorbide mononitrate in a slow-released formulation for oral administration, is indicated for the prevention and long-term treatment of angina pectoris associated with coronary artery disease. ISMN relaxes blood vessels, increasing the blood and oxygen supply to the heart. It reduces the pressure that the heart has to pump against and hence the Heart's work and need for oxygen, and also increases supply of oxygen to the heart by dilating the arteries which supply the heart itself. Isosorbide mononitrate is in the class of drugs called anti-anginal medications….
(Hong Kong, 29 March 2005) - Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that the Group has signed a Supply and Distribution Agreement with Marvecs Services S.r.l. for the distribution and marketing of Vasdilat®...
know more
know more
30/06/2022
License Transfer from Solasia to Lee’s Pharm for the Sales Promotion of Sancuso® and episil® in three cities in China
21/06/2022
New product Teglutik® obtained Drug Registration Certificate
20/05/2022
New product Natulan® obtained Drug Registration Certificate
22/04/2022
New product “Nitric Oxide for Inhalation” (INOmax®) was approved for commercialization in China
12/04/2022
Signing of the Comprehensive Strategic Cooperation Agreement between Lee’s Pharm and Rongtai Pharmaceutical
05/04/2022
Launching of Lee’s Pharm Flagship Store on Ali’s and Jingdong’s e-commerce platforms in China
13/01/2022
Zhaoke-Hefei was honoured with the award of “2021 Anhui Provincial Role Model Enterprise in Consumer Products Industry”
01/01/2022
Listing on Guidance for Family Choice Pharmacy of Lee’s Pharm signature products — Ferplex® and Yallaferon®
01/01/2022
“STEM Experience Program for Secondary Students — Kanya Lee Scholarship Recognition Ceremony”
29/12/2021
Lee’s Pharm in-house product Yallaferon® was honoured with “2021 Biopharmaceutical Excellent Brand” Award
23/12/2021
Dr. Li Xiaoyi, the founder of Lee’s Pharm was recognized as “High-Level Talent in Guangzhou Nansha New Zone (Free Trade Zone)”
23/12/2021
Lee’s Pharm Mask Donation Campaign, Sending warmth and care to the community
17/09/2021
Zhaoke Oncology was honoured with “2020 Guangzhou High-end, Precision and Sophisticated Firms” Award
03/09/2021
Zhaoke-Hefei was honoured with the award of “Anhui Provincial High-End Brand Cultivation Demonstration Enterprise in Manufacturing Industry”
24/08/2021
Baptist’s Charity Campaign for World Vision International with sponsorship from Lee’s Pharm
23/08/2021
Patented Technology “Purification of Snake Venom from Viperidae” developed by Zhaoke-Hefei was honoured with “The 8th Anhui Provincial Patent Excellence Award”
26/07/2021
Lees Pharm was honoured with 2020 Top 100 ranking of Chinese Chemical Pharmaceutical Companies
24/06/2021
The New Product “Sodium Phenylbutyrate” from Lee’s Pharm — Bringing hope to rare disease patients — Lee’s Pharm participated in the Multidisciplinary Expert Seminar on Urea Cycle Disorders
07/06/2021
Lee’s Pharm attended the Rare Diseases Conference of Guangdong Medical Association
04/06/2021
Lee’s Pharm Sponsored Symposium at the Sexual Medicine Course for Providers of Women’s Health Care
21/10/2020
HKSTP InnoAcademy — Technology Leaders of Tomorrow programme
20/10/2020
Dr Benjamin Li, CEO of Lee’s Pharmaceutical Holdings Limited was interviewed by TVB on 15 October 2020 sharing our unique concept of mask production by Powder Pharmaceuticals Incorporated (Interview Video)
20/10/2020
Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets
11/10/2020
Concludes Series B Fundraising of approximately US$145 million for Zhaoke Ophthalmology — Marks Big Step Towards Achieving Possible Spin-off and Separate Listing
10/03/2020
HKBIO and Lee’s Pharm Mask Donation Campaign
03/03/2020
Donation of ERT-PCR Technology for New Coronavirus Detection Press Conference
30/10/2019
Lee’s Pharm Cardiovascular Products Meeting of the 30th GW-ICC
29/10/2019
Greater Pediatrics, Greater Kids, Greater China ——Ferplex of Lee’s Pharmaceutical Holdings Ltd. appeared in the 24th Congress of Chinese Pediatric Society
21/10/2019
Pre-IND meeting to communicate the combination of recombinant fully human anti- PD-L1 monoclonal antibody injection (ZKAB001 for short) and vaccinia GM-CSF/TK inactivated virus (Pexa-Vec, oncolytic virus)
14/10/2019
Building a Bridge; China-Italy Cooperation in Medical Education
24/09/2019
Wen Guohui, Deputy Secretary of the CPC Guangzhou Municipal Committee and Mayor of Guangzhou visited Zhaoke Pharmaceutical (Guangzhou) Ltd.
09/09/2019
Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd.had a very successful meeting with the reviewers from the Center for Drug Evaluation of NMPA of China
01/09/2019
East Meets West – Lee’s Pharm 9th Perinatal Medical Forum in Beijing
20/08/2019
INOMAX pre-NDA meeting
02/04/2019
RegeneRx and Lee’s Pharm to Accelerate RGN-259 Development in China
20/12/2018
Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia
06/09/2018
SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in ChinaPhase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
14/02/2018
GC Pharma and Lee’s Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
08/02/2018
CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 MONOCLONAL ANTIBODY
22/11/2017
Eleison Pharmaceuticals to Partner with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, to Develop and Commercialize Glufosfamide for the China Market
21/11/2017
Shenogen Pharma and Lee’s Pharm entered into a Collaboration Agreement for a Combination Product for Treatment of Late Stage Cancers
02/11/2017
Windtree and Lee’s Pharm Close $10 Million Share Purchase Agreement Giving Lee’s Pharm Controlling Interest in Windtree
04/10/2017
Appointment Of Ms. Zhang Zhen Hua, Ada As Group Director Of Human Resources And Development Of Lee’s Pharmaceutical Holdings Limited
21/08/2017
Zingo® for Needle-free Local Analgesia is approved by Hong Kong Department of Health
26/07/2017
SillaJen and Lee’s Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
29/06/2017
Adapalene and Clindamycin combination hydrochloride Gel meets pre-specified endpoints in Phase Ib-IIa clinical study in Acne Vulgaris (Moderate to severe acne)
13/06/2017
Windtree Therapeutics and Lee’s Pharmaceutical (HK) Limited Enter Into Exclusive License and Collaboration Agreement for Development and Commercialization of KL4 Surfactant Technology Platform in Asia
09/03/2017
China FDA has Approved Zingo® for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial
27/02/2017
05/01/2017
Dilaforinitiates phase IIb clinical trial with tafoxiparin in women with slow progress of labor
05/01/2017
TOT BIOPHARM and LEE’S PHARM Signed an Exclusive Licensing Agreement on Monoclonal Antibody Drug TAB014
03/01/2017
First patient enrolled in Registration Study of Natulan® for patients with advanced Hodgkin’s lymphoma in China
02/12/2016
CVieTherapeutics Enrolled the First Patient in Phase 2b Clinical Study of Istaroxime in China
14/11/2016
Submitted New Drug Application to China FDA and Hong Kong DHon Zingo® for Needle-free Local Analgesia
07/10/2016
Kato Pharmaceuticals, Inc. and Lee’s Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize Resolvine ER in Greater China and South East Asia
27/09/2016
Dilafor raises SEK 51 million to facilitate Phase IIb clinical study with Tafoxiparin
09/09/2016
Completed The First Subject in Clinical Study for Continuous Glucose Monitoring System in Hong Kong
25/08/2016
Beijing Shenogen Pharma Group Limited and Lee’s Pharmaceutical (HK) Limited Announce Development and Commercialization Collaboration Agreement for Pexa-Vec and Icaritin in China
04/07/2016
China FDA Grants Pharmaceutical Manufacturing License to Nansha Manufacturing Facility
16/06/2016
Lee’s Pharm Announces its Chief Executive Officer, Dr. Benjamin Xiao-Yi Li awarded Honorary Fellowship from The Hong Kong University of Science and Technology
02/06/2016
RegeneRx and Lee’s Pharm Announce Acceleration of RGN-259 Development in China
16/05/2016
APPOINTMENT OF DR. LIT-FUI LAU AS PRESIDENT AND CHIEF OPERATING OFFICER OF CVIE THERAPEUTICS LIMITED
14/04/2016
14/04/2016
14/04/2016
14/04/2016
14/04/2016
14/04/2016
14/04/2016
24/03/2016
24/03/2016
24/03/2016
24/03/2016
U.S. FDA Grants Orphan Drug Designation to Anfibatide for Treatment of Thrombotic Thrombocytopenic Purpura
14/03/2016
Successful FDA Inspection with No 483 Issued to Powder Pharmaceuticals
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
23/02/2016
04/01/2016
Salvat and Lee’s Pharmaceutical (HK) Limited Announce Exclusive License and Supply Agreement for Duoxal® in Greater China
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
31/12/2015
22/12/2015
CVie Therapeutics enrolled the 1st patient for Phase 2b Clinical Trial of Rostafuroxin in Taiwan
08/12/2015
Lee’s Pharm was honored at 2015’s Forbes Asia “Best Under A Billion” Award Ceremony
08/12/2015
Lee’s Pharm Announces its Chief Executive Officer, Dr. Benjamin Li wins the EY Entrepreneur Of The Year® 2015 China Award
25/11/2015
Solasia and Lee’s Pharma Announce License, Promotion and Supply Agreement (the “Agreement”) for Sancuso®
17/11/2015
Tragara and Lee’s Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize TG02 in Greater China Market and South East Asia
28/10/2015
First Patient enrolled in Phase IIb Clinical Trial of Anfibatide in China
22/09/2015
Armetheon and Lee’s Pharma Enter into Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand
11/09/2015
Recently Published Study Shows Positive Results for ZiNGO® in Pediatric Patients
26/08/2015
WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee’s Pharm
24/08/2015
BioQuiddity and Lee’s Pharmaceutical Enter Agreement to Jointly Commercialize – Two Infusion Pharmaceuticals in China, Taiwan, Hong Kong, and Macau
03/08/2015
CVIE Therapeutics obtained approval from the Ministry of Health and Welfare for conducting Phase 2b Clinical Trial of Rostafuroxin in Taiwan
03/07/2015
Presentation at The First Chinese Symposium of Thrombosis and Haemostasis in Association with the ISTH Congress
30/03/2015
First patient enrolled in Phase Ib-IIa clinical studyof Adapalene and Clindamycin combination hydrochloride Gel for Acne Vulgaris (Moderate to severe acne)
09/03/2015
Lee’s Pharm Joins Hang Seng Broad Consumption Index, Hang Seng Mainland Consumer Goods Index, Hang Seng Global Composite Index and Hang Seng Composite Index
26/02/2015
Lee’s Zhaoke Pharmaceutical Ranks Second in 2014 for Number of Declared New Drug Application
27/11/2014
EyeSense Attracts Lee’s Pharmaceutical Holdings as Strategic Investor
19/11/2014
Ikaria and Lee’s Pharmaceutical Announce Strategic Partnership for the Registration and Commercialization of Ikaria’s INOMAX ® Total Care Package in the PRC, HK, Macau and Taiwan
12/11/2014
Patients Enrollment Completed in Phase II Clinical Study of Anfibatide in China
12/11/2014
Lee’s Pharmaceutical successfully obtained the Imported Drug License for MICTONORM® in China
10/11/2014
Lee’s Pharm Becomes a Constituent Stock of MSCI China Index under MSCI Global Small Cap Indexes
06/10/2014
SORRENTO AND LEE’S PHARMACEUTICAL ENTER INTO EXCLUSIVE CHINA LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE ANTI-PD-L1 ANTIBODY
01/10/2014
01/10/2014
01/10/2014
01/10/2014
08/09/2014
License, Distribution and Supply Agreement to market Cholecalciferol in China, Hong Kong, Macau and Taiwan
01/09/2014
01/09/2014
01/09/2014
01/09/2014
01/09/2014
01/09/2014
01/08/2014
01/08/2014
01/08/2014
01/08/2014
01/07/2014
01/07/2014
01/07/2014
23/06/2014
Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye
01/06/2014
01/06/2014
09/05/2014
ScinoPharm and Lees Pharmaceutical Jointly Develop a Number of Drug Products for the Chinese Market
01/05/2014
01/05/2014
01/05/2014
01/05/2014
01/05/2014
01/05/2014
01/05/2014
01/05/2014
16/04/2014
License, Distribution and Supply Agreement to market Neridronic Acid in China, Hong Kong, Macau and Taiwan
01/04/2014
01/04/2014
03/03/2014
Powder Pharmaceuticals Hong Kong made the first shipment to US
01/03/2014